CLINICAL TRIALS PROFILE FOR BRONCHO SALINE
✉ Email this page to a colleague
All Clinical Trials for Broncho Saline
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00029328 ↗ | Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation | Completed | FDA Office of Orphan Products Development | Phase 1/Phase 2 | 2001-09-01 | The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation. |
| NCT00041561 ↗ | Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics | Terminated | Mallinckrodt | Phase 3 | 2002-01-01 | The purpose of this study is to determine the effect of nitric oxide for inhalation on the duration of mechanical ventilation in pediatric patients with AHRF. |
| NCT00127985 ↗ | 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome | Unknown status | Pfizer | Phase 4 | 2005-08-01 | Background: Systemic corticosteroids are considered in patients with an adverse clinical course suffering from conditions like the acute respiratory distress syndrome (ARDS) and septic shock. Treated patients not only show improved respiratory function, but also hemodynamic status and overall multiple organ dysfunction score. Objective: To evaluate the safety and effectiveness of 6-methyl-prednisolone on the clinical course of multiple organ dysfunction syndrome (MODS). Design: Multi-center, double-blind, randomized, placebo-controlled. Intervention: Intravenous administration of 6-methyl-prednisolone or placebo (aqueous solution). The duration of the study medication administration protocol is 32 days (1). Primary Endpoints: 1. All cause Intensive Care Unit (ICU) and 28-day mortality 2. Organ dysfunction score on days 4, 7, 14, and 28 of the protocol. |
| NCT00127985 ↗ | 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome | Unknown status | Hospital Universitario Principe de Asturias | Phase 4 | 2005-08-01 | Background: Systemic corticosteroids are considered in patients with an adverse clinical course suffering from conditions like the acute respiratory distress syndrome (ARDS) and septic shock. Treated patients not only show improved respiratory function, but also hemodynamic status and overall multiple organ dysfunction score. Objective: To evaluate the safety and effectiveness of 6-methyl-prednisolone on the clinical course of multiple organ dysfunction syndrome (MODS). Design: Multi-center, double-blind, randomized, placebo-controlled. Intervention: Intravenous administration of 6-methyl-prednisolone or placebo (aqueous solution). The duration of the study medication administration protocol is 32 days (1). Primary Endpoints: 1. All cause Intensive Care Unit (ICU) and 28-day mortality 2. Organ dysfunction score on days 4, 7, 14, and 28 of the protocol. |
| NCT00363805 ↗ | Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease | Completed | National Cancer Institute (NCI) | Phase 2 | 2004-05-01 | RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. The use of green tea or polyphenon E may prevent cancer from forming in former smokers with chronic obstructive pulmonary disease. PURPOSE: This randomized phase II trial is studying how well green tea or polyphenon E work in preventing lung cancer in former smokers with chronic obstructive pulmonary disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Broncho Saline
Condition Name
Clinical Trial Locations for Broncho Saline
Trials by Country
Clinical Trial Progress for Broncho Saline
Clinical Trial Phase
Clinical Trial Sponsors for Broncho Saline
Sponsor Name
